TREGSHIELD BIO Inc.

TregShield Bio is a next-generation immunology biotech pioneering tissue-restricted activation of biologics for safer, more effective treatment of immune and inflammatory (I&I) diseases. Unlike conventional biologics that start acting systemically, our platform ensures activation only in diseased organs — unlocking powerful immune modulation safely. First priority- helping people with Type 1 Diabetes (T1D) with safer, more effective disease-modifying treatment options. TRS-001 is our first-in-class, pancreas-activable biologic for T1D, featuring a dual mechanism of action: • Neutralizing pathogenic T cells • Boosting regulatory T cells Beyond T1D, our platform is designed to expand across multiple high-value I&I indications. At TregShield Bio, we believe in delivering the right drug, to the right patient, at the right location. An Elite Team united by Innovation, Built to Execute We bring together a uniquely complementary team of proven drug developers & biotech innovators with deep expertise across: • Antibody engineering & immunology • Translational & clinical drug development • Biologics CMC & manufacturing • Corporate strategy, BD, & licensing Collectively, our team delivered marketed therapeutics, clinical-stage assets, & multi-million dollar licensing deals. We’re united by innovation, patient impact, & a mission to bring safer biologics to life — organ by organ. Meet our team: 🔹 Fabien Dépis, Ph.D. – Founder, President & CEO 🔹 Maureen Deehan, Ph.D. – Independent Board Member | Corp Dev & Licensing 🔹 Olivier Léger, Ph.D. – Sr. Advisor | Antibody Engineering & Company Creation 🔹 Changyun Hu, Ph.D. – Advisor | Antibody Engineering & Immunology 🔹 Greg Elson, Ph.D. – Sr. Advisor | Biologics CMC & Product Dev 🔹 Silvia Caluwaerts, Ph.D. – Advisor | Translational & Clinical Dev We're actively seeking mission-aligned investors, strategic biopharma partners, and supporting foundations. Let’s build the future of precision biologics — one organ at a time